PET scans may predict which breast cancer patients benefit from elacestrant
NCT ID NCT07753954
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily, and researchers will use imaging to see if the pattern of estrogen receptors in tumors affects treatment outcomes. The goal is to learn if this imaging approach can guide more personalized treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- elacestrant, an oral drug that blocks and degrades estrogen receptors
- What this could lead to
- If successful, this could show that PET imaging helps doctors choose the best treatment for advanced breast cancer, potentially improving outcomes.
- What could go wrong
- This is a phase 2 trial with no comparison group, so results may not be definitive. The drug may cause side effects, and imaging may not reliably predict who benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+ / HER2- ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.